The estimated Net Worth of Timothy C Dec is at least $484 Tisíc dollars as of 13 October 2023. Mr Dec owns over 4,000 units of Opgen Inc stock worth over $14,140 and over the last 9 years he sold OPGN stock worth over $0. In addition, he makes $470,000 as CFO & Corp. Sec. at Opgen Inc.
Mr has made over 10 trades of the Opgen Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of OPGN stock worth $8,080 on 13 October 2023.
The largest trade he's ever made was buying 65,000 units of Opgen Inc stock on 18 July 2017 worth over $26,000. On average, Mr trades about 4,151 units every 90 days since 2015. As of 13 October 2023 he still owns at least 7,000 units of Opgen Inc stock.
You can see the complete history of Mr Dec stock trades at the bottom of the page.
Timothy C. Dec is the CFO & Corp. Sec. at Opgen Inc.
As the CFO & Corp. Sec. of Opgen Inc, the total compensation of Mr Dec at Opgen Inc is $470,000. There are 2 executives at Opgen Inc getting paid more, with Dr. Oliver Schacht having the highest compensation of $565,869.
Mr Dec is 61, he's been the CFO & Corp. Sec. of Opgen Inc since . There are 1 older and 6 younger executives at Opgen Inc. The oldest executive at Opgen Inc is Dr. G. Terrance Walker Ph.D., 62, who is the Sr. VP of R&D.
Timothy's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Opgen Inc have traded over $12,018 worth of Opgen Inc stock and bought 4,331,782 units worth $1,198,700 . The most active insiders traders include Evan/ Fa Jones, Capital, Llcjones Evan/ Fa ... a Capital, Llc J Ven. On average, Opgen Inc executives and independent directors trade stock every 78 days with the average trade being worth of $280,277. The most recent stock trade was executed by Johannes Bacher on 31 March 2023, trading 6,434 units of OPGN stock currently worth $12,997.
opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.
Opgen Inc executives and other stock owners filed with the SEC include: